US · Healthcare · Medical Devices
EPS came in at -0.53 against a street estimate of -0.62 — a beat of 14.5%.
Analysts rate Beta Bionics, Inc. Common Stock a buy (10 buy, 4 hold, 0 sell out of 14) with an average price target of $24.24.
| Fund | Stake |
|---|---|
| Eventide Asset Management, LLC | 11.59% |
| Soleus Capital Management, L.P. | 8.14% |
| Morgan Stanley - Brokerage Accounts | 7.91% |
| Sands Capital Ventures, LLC | 6.87% |
| BlackRock Inc | 6.19% |
| Point72 Asset Management, L.P. | 4.18% |
| Vanguard Capital Management, LLC | 3.30% |
| Vestal Point Capital LP | 2.97% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 BETA BIONICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company conducting public offering of 7,652,175 shares at $17.25 per share • Additional 1,043,48 | 2026-09-17 |
| Reg FD disclosure · Q3 2026 BETA BIONICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • FDA cleared Mint patch pump on September 14, 2026 • iLet real-world data: 84% of users met Ameri | 2026-09-15 |
| Quarterly report · Q2 2026 BETA BIONICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net sales for Q2 2026: $32.0 million (up 38% from $23.2 million in Q2 2025) • Net sal | 2026-07-29 |
| Results announced · Q3 2026 BETA BIONICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net sales: $32.0 million in Q2 2026, up 38% from $23.2 million in Q2 2025 • Six-mo | 2026-07-29 |
| Shareholder vote results · Q2 2026 BETA BIONICS, INC. (BBNX) - FORM 8-K SUMMARY HEADLINE NUMBERS • Company held 2026 Annual Meeting of Stockholders on May 21, 2026 • 44,561,695 total | 2026-05-22 |
| Reg FD disclosure · Q2 2026 BETA BIONICS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Beta Bionics, Inc. (ticker: BBNX, Nasdaq) • Report date: May 21, 2026 • Headquarte | 2026-05-21 |
| Quarterly report · Q1 2026 BETA BIONICS, INC. — FORM 10-Q SUMMARY Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Net Sales: $27.6 million (Q1 2026) vs. $17.6 m | 2026-04-21 |
| Results announced · Q2 2026 BETA BIONICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net sales: $27.6 million, up 57% from $17.6 million in Q1 2025 • Gross margin: 59. | 2026-04-21 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Beta Bionics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.